33 results about "Vaccine therapy" patented technology

The present invention provides a novel method that can increase readily a virus or viral vector concentration in a solution having a low concentration and a kit for performing the method. Conventional methods require complicated operations, expensive equipment, or highly trained experts for efficiently concentrating viruses from low-concentration virus solutions. The method of the present invention can concentrate viral vectors readily while maintaining infection abilities of the viral vectors, and thus it can be used as a safe and simple technique for concentrating a vector useful in the field of a genetic therapy or a vaccine therapy using a viral vector.

An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.

To provide a virus vector which can be used for producing a prime / boost vaccine that can activate both cellular immunity and humoral immunity and is effective on infections by pathogenic microorganisms and malignant tumors which are generally believed to be difficult to be treated by vaccine therapy. Provided is a virus vector for prime / boost vaccines, comprising the following components (a) and (b): (a) a vaccinia virus vector which carries a gene encoding an immunogenic polypeptide in such a manner that the gene can be expressed; and (b) a Sendal virus vector which carries the gene encoding the immunogenic polypeptide in such a manner that the gene can be expressed.

Continuous cell lines that are highly permissive to infection by porcine circovirus type 2 (“PCV2”) are described. PCV2 is the causal agent of post-weaning multi-systemic wasting syndrome (“PMWS”) in pigs. PMWS has emerged as a major disease that poses a significant threat to the economics of global swine industry. The highly permissive cell lines of this invention provide efficient and reliable sources of PCV2 for use in development of vaccines, therapies and diagnostic agents for PMWS.

[Problem]To provide a set of virus vectors which can be used for producing a prime / boost vaccine that can activate both cellular immunity and humoral immunity and is effective on infections by pathogenic microorganisms and malignant tumors which are generally believed to be difficult to be treated by vaccine therapy.[Solution]Provided is a set of virus vectors for prime / boost vaccines, comprising the following virus vector (a) and virus vector (b): (a) a vaccinia virus vector which carries a gene encoding an immunogenic polypeptide in such a manner that the gene can be expressed; and (b) a Sendal virus vector which carries the gene encoding the immunogenic polypeptide in such a manner that the gene can be expressed.

The invention discloses the field of tumor cellular immunotherapy and particularly relates to a tumor cell vaccine which is modified by a PD-1 neutralizing antibody with combination of a GM-CSF factor and a preparation method thereof. In the invention, tumor cellular vaccine therapy is creatively combined with antibody therapy which relieves tumor immune-suppression, so that the prepared tumor cell vaccine simultaneously secreting the PD-1 neutralizing antibody and the GM-CSF factor can not only relieve the immune-suppression status of a tumor micro-environment but also enhance an antitumor immune reaction. The tumor cell vaccine is good in antitumor treatment effect, is excellent in development value and provides a new approach of tumor cellular immunotherapy.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2 / Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and / or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

The invention provides compositions and methods for making and using modified viruses, including infectious viruses, having an external surface linked to at least one heterologous unnatural moiety that is exemplified by unnatural amino acid and unnatural saccharide. The unnatural moiety that is linked to the invention's modified viruses is optionally further linked to a molecule of interest (such as probe, cytotoxin, therapeutic molecule, antibody, affibody, epitope, etc. The invention's compositions and methods for use in, for example, diagnostic applications and therapeutic applications such as gene therapy, oncolytic therapy, and / or vaccine therapy.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and / or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The object of the present invention is to clarify functions of XAGE-1b and to develop a vaccine therapy for cancer based on XAGE-1b. Humoral immunity or cellular immunity is induced against XAGE-1b in lung cancer, by use of a peptide comprising an amino acid sequence of any one of (a) through (e) or by use of a peptide comprising an amino acid sequence of any one of (f) through (k).

The invention disclosed herein aims to standardize and simplify the process of preparing Ex-Vivo autologous whole tumor cell vaccines. The present invention is a robust, stand-alone device and system for preparing autologous tumor cell vaccines in a completely self-contained sterile environment, and in a shortened time. This new device and system will process the extracted tumor with its associated stromal and endothelial cells into injectable tumor cell vaccines, administered automatically or semi-automatically. This invention incorporates a number of new biotechnologies to enhance therapeutic effects over other existing methods. This invention will allow a medical facility to prepare and administer autologous cancer cell vaccine therapy independently without having, or using, a GMP facility, while adhering to and maintaining GMP guidelines.

The present invention relates to pharmaceutical / immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for prostate tumours in humans, to immunogenic compositions containing them, to methods of manufacture of such compositions and to their use in medicine. Methods for formulating vaccines for immunotherapeutically treating P501S-expressing prostate tumors, prostatic hyperplasia, and prostate intraepithelilial neoplasia (PIN) are also provided.

This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

The invention discloses redox sensitive polypeptide based on cell-penetrating peptide and application of the redox sensitive polypeptide in a vaccine vector. The sequence of the polypeptide is shown by SEQ ID NO:1. The polypeptide can be subjected to an electrostatic interaction with an antigen carrying a negative charge first, then cross-linking is performed with sulfydryl of cysteine, and the antigen is tightly wraped to form a stable polypeptide / antigen nano composite. In the nano composite, the sulfydryl of cysteine conducts spontaneous oxidation to form a disulfide bond, and the polypeptides are subjected to cross-linking to form a denser peptide / antigen condensation product. The redox sensitive polypeptide disclosed by the invention integrates the advantages of cell-penetrating peptide and the redox responding type disulfide bond cross-linking agent; by adopting new cell-penetrating peptide mediated redox responding type polypeptide as a vaccine adjuvant, the redox sensitive polypeptide overcomes the shortcoming that traditional immunologic adjuvant cannot induce an organism to generate strong antigen-specific cellular immunity, and is expected to be applied to clinical vaccine therapy.

This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.

The present invention provides a method of making a proteinase-engineered cancer vaccine for treating a cancer patient, especially for cancer patient at advanced / metastatic stage. The cancer vaccine comprises dead cancer cells with unbroken plasma membrane wherein the extracellular proteins and extracellular portion of membrane proteins are cleaved by proteinase digestion. The cancer vaccine may be derived from cancer cell lines or patients' cancer cells. The present invention provides a method of treating a cancer patient by administrating an effective amount of the cancer vaccine to the patient. In a clinical trial with 35 cancer patients, the cancer vaccine therapy brings cancer-free lives (no detectable tumor, micro tumor or cancer cells after treatment) back to 40% of these patients. The cancer vaccine therapy for the first time brings the promise of cure to this deadly disease. The present invention further provides a method of obtaining cancer-specific immune components from blood of individuals treated with the cancer vaccine.

We provide the application of intracellular antibody therapy to target intracellular oncoproteins or proteins to prevent cancer metastasis. We also provide the use of intracellular vaccine therapy comprising oncoprotein proteins for vaccination to stimulate the host to produce its own antibodies to prevent tumor formation. Antibodies can include chimeric antibodies.

The invention discloses quaternary phosphonium chitosan and application of the quaternary phosphonium chitosan serving as a vaccine immune adjuvant. The preparation method of the quaternary phosphonium chitosan comprises the following steps: adding chitosan and 1-hydroxybenzotriazole into a solvent, so as to be subjected to ice bath reaction, and then adjusting the pH value to 4.8 to 5.5; then adding 3-hydroxypropyl triphenyl phosphorus bromide, and stirring the 3-hydroxypropyl triphenyl phosphorus bromide till the 3-hydroxypropyl triphenyl phosphorus bromide is completely dissolved; dissolving the 1-ethyl-(3-dimethylaminopropyl) carbodiie hydrochlide into the solvent, adding the 1-ethyl-(3-dimethylaminopropyl) carbodiie hydrochlide into a reaction system, precipitating, drying and dialyzing a product after reaction, and obtaining the quaternary phosphonium chitosan after freeze drying is performed. The quaternary phosphonium chitosan is taken as a vaccine immune adjuvant for the first time, and can promote the uptaking to antigen by DC2.4 cell, promote splenocyte proliferation, and induce higher levels of antigen-specific IgG antibody titer, IFN-gamma, IL-4 and IL-10, thereby having a significant application value in the field of vaccine therapy.

The invention discloses an application of phosphorylated chitosan as an immuno-adjuvant in vaccine therapy and belongs to the field of biomaterials and immuno-treatment. In the invention, for the first time, the phosphorylated chitosan serves as the immuno-adjuvant; compared with conventional immuno-adjuvants, the phosphorylated chitosan is easy to synthesize and is low in cost, and has excellent biodegradability and biocompatibility and has no damage on both organisms and environment. The phosphorylated chitosan is good in water-solubility and can be applied in in-vivo environment well without adverse toxic and side effects. The phosphorylated chitosan, as an immuno-adjuvant, can significantly induce higher-level antigen-specificity IgG antibody titer, promote immuno-reaction of IFN-gamma / IL-4 cell factor and CD4<+> / CD8<+> T lymphocytes and activate dendritic cells better, thereby enhancing immunogenicity of a vaccine and effectively improving antigen-specific immune response of organisms, so that the phosphorylated chitosan has important application value in the field of vaccine therapy.

An agent for use in a vaccine therapy to prevent or treat a Burkholderia infection in a mammal, wherein the agent is selected from a polypeptide of SEQUENCE ID NO:1, or a therapeutically effective variant thereof having at least 90% sequence identity with SEQUENCE ID NO: 1; a polypeptide of SEQUENCE ID NO:3, or a therapeutically effective variant thereof having at least 90% sequence identity with SEQUENCE ID NO: 3; and an immunogenic portion of the polypeptides of SEQUENCE ID NO:1 or SEQUENCE ID NO:3.

The invention discloses quaternary phosphonium chitosan and application of the quaternary phosphonium chitosan serving as a vaccine immune adjuvant. The preparation method of the quaternary phosphonium chitosan comprises the following steps: adding chitosan and 1-hydroxybenzotriazole into a solvent, so as to be subjected to ice bath reaction, and then adjusting the pH value to 4.8 to 5.5; then adding 3-hydroxypropyl triphenyl phosphorus bromide, and stirring the 3-hydroxypropyl triphenyl phosphorus bromide till the 3-hydroxypropyl triphenyl phosphorus bromide is completely dissolved; dissolving the 1-ethyl-(3-dimethylaminopropyl) carbodiie hydrochlide into the solvent, adding the 1-ethyl-(3-dimethylaminopropyl) carbodiie hydrochlide into a reaction system, precipitating, drying and dialyzing a product after reaction, and obtaining the quaternary phosphonium chitosan after freeze drying is performed. The quaternary phosphonium chitosan is taken as a vaccine immune adjuvant for the first time, and can promote the uptaking to antigen by DC2.4 cell, promote splenocyte proliferation, and induce higher levels of antigen-specific IgG antibody titer, IFN-gamma, IL-4 and IL-10, thereby having a significant application value in the field of vaccine therapy.

The invention discloses redox sensitive polypeptide based on cell-penetrating peptide and application of the redox sensitive polypeptide in a vaccine vector. The sequence of the polypeptide is shown by SEQ ID NO:1. The polypeptide can be subjected to an electrostatic interaction with an antigen carrying a negative charge first, then cross-linking is performed with sulfydryl of cysteine, and the antigen is tightly wraped to form a stable polypeptide / antigen nano composite. In the nano composite, the sulfydryl of cysteine conducts spontaneous oxidation to form a disulfide bond, and the polypeptides are subjected to cross-linking to form a denser peptide / antigen condensation product. The redox sensitive polypeptide disclosed by the invention integrates the advantages of cell-penetrating peptide and the redox responding type disulfide bond cross-linking agent; by adopting new cell-penetrating peptide mediated redox responding type polypeptide as a vaccine adjuvant, the redox sensitive polypeptide overcomes the shortcoming that traditional immunologic adjuvant cannot induce an organism to generate strong antigen-specific cellular immunity, and is expected to be applied to clinical vaccine therapy.

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

The present invention provides methods of preventing or reducing the risk of recurrence of endometrial and ovarian cancers which express low levels of folate binding protein (FBP) by administration of a vaccine containing an E39 peptide.